The FDA has approved orforglipron (Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.1
MECHANISM OF ACTION ― Activation of...
- Lerodalcibep (Lerochol) for Hypercholesterolemia
- Leucovorin for Cerebral Folate Deficiency
- In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss
- In Brief: RSV Vaccine (Arexvy) for Ages 18-49
- In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction
- Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (online only)
- Nipocalimab (Imaavy) for Myasthenia Gravis (online only)
ISSUE
The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been available in single-ingredient ophthalmic solutions for other indications for years.
PRESBYOPIA — Presbyopia is a common age-related condition characterized by gradual loss of clear near vision. It is thought to be caused by loss of lens elasticity and weakening of ciliary muscles, reducing the ability for near-focus accommodation.
STANDARD TREATMENT — Corrective lenses (glasses and contact lenses) are the first-line treatment of presbyopia. Ophthalmic solutions of the muscarinic agonist pilocarpine (Qlosi, Vuity) and the cholinergic agonist aceclidine (Vizz) have improved near visual acuity in patients with …